Stock research
REVB Revelation Biosciences, Inc.
Healthcare • Biotechnology
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system....…
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
5Y change
-100.00%
Range high
$1,864,797.12
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in REVB?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $0.95
- Day High
- $1.03
- Day Low
- $0.98
- 52w High
- $11.72
- 52w Low
- $0.88
- Volume
- 16,160.8875
- Avg Volume
- Beta
- -0.117
* TTM/most recent where available
Company
- Ticker
- REVB
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- James Rolke
- Employees
- 8
- Website
- www.revbiosciences.com
Key Metrics
- Market Cap
- 4.03M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).